Literature DB >> 9863476

Opposing time trends of peptic ulcer and reflux disease.

H B el-Serag1, A Sonnenberg.   

Abstract

BACKGROUND: Gastritis associated hypochlorhydria may be protective against gastro-oesophageal reflux disease. It was hypothesised that the historic decline in Helicobacter pylori infection resulted in a decline in peptic ulcer and a concomitant risk in reflux disease. AIMS: To study the time trends of peptic ulcer and reflux disease.
METHODS: Hospitalisation rates were analysed using the computerised database of the US Department of Veterans Affairs from 1970 until 1995. Death rates were calculated from the Vital Statistics of the United States.
RESULTS: From 1970 to 1995, hospitalisation rates for gastric and duodenal ulcer, as well as gastric cancer fell, while the hospitalisation rates for gastro-oesophageal reflux disease and those for oesophageal adenocarcinoma rose significantly. Similar time trends were observed with respect to the death rates. There were notable ethnic differences. White subjects incurred higher rates of reflux disease and oesophageal adenocarcinoma and lower rates of gastric ulcer or cancer compared with non-whites.
CONCLUSIONS: The ethnic variations and the opposing time trends of gastroduodenal versus oesophageal disease are consistent with the hypothesis that the declining infection rates of H pylori in the general population have led to a rise in the occurrence of gastro-oesophageal reflux disease and associated oesophageal adenocarcinoma.

Entities:  

Mesh:

Year:  1998        PMID: 9863476      PMCID: PMC1727258          DOI: 10.1136/gut.43.3.327

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  34 in total

1.  Cancer statistics, 1992.

Authors:  C C Boring; T S Squires; T Tong
Journal:  CA Cancer J Clin       Date:  1992 Jan-Feb       Impact factor: 508.702

2.  Surgical treatment of peptic ulcer in the United States. Trends before and after the introduction of cimetidine.

Authors:  H V Fineberg; L A Pearlman
Journal:  Lancet       Date:  1981-06-13       Impact factor: 79.321

3.  The complex wane of peptic ulcer. I. Recent national trends in deaths and hospital care in the United States.

Authors:  C M Wylie
Journal:  J Clin Gastroenterol       Date:  1981-12       Impact factor: 3.062

4.  20 years of hospital admissions for peptic ulcer in England and Wales.

Authors:  D Coggon; P Lambert; M J Langman
Journal:  Lancet       Date:  1981-06-13       Impact factor: 79.321

5.  Decline in duodenal ulcer surgery.

Authors:  M P Smith
Journal:  JAMA       Date:  1977-03-07       Impact factor: 56.272

6.  Disability pensions due to peptic ulcer in Germany between 1953 and 1983.

Authors:  A Sonnenberg
Journal:  Am J Epidemiol       Date:  1985-07       Impact factor: 4.897

Review 7.  Role of Helicobacter pylori in the pathogenesis of gastritis, peptic ulcer and gastric cancer.

Authors:  P Sipponen; H Hyvärinen
Journal:  Scand J Gastroenterol Suppl       Date:  1993

8.  Trends in hospital admissions and death rates for peptic ulcer in the United States from 1970 to 1978.

Authors:  J D Elashoff; M I Grossman
Journal:  Gastroenterology       Date:  1980-02       Impact factor: 22.682

9.  Helicobacter pylori in Hispanics: comparison with blacks and whites of similar age and socioeconomic class.

Authors:  H M Malaty; D G Evans; D J Evans; D Y Graham
Journal:  Gastroenterology       Date:  1992-09       Impact factor: 22.682

10.  Time trends in peptic ulcer disease and in gastritis and duodenitis. Mortality, utilization, and disability in the United States.

Authors:  B S Bloom; E Kroch
Journal:  J Clin Gastroenterol       Date:  1993-12       Impact factor: 3.062

View more
  79 in total

1.  Gastroesophageal reflux and Helicobacter pylori: a review.

Authors:  F Pace; G Bianchi Porro
Journal:  World J Gastroenterol       Date:  2000-06       Impact factor: 5.742

2.  The prevalence of Barrett's esophagus and erosive esophagitis in patients undergoing upper endoscopy for dyspepsia in a VA population.

Authors:  Michael J Connor; Allan P Weston; Matthew S Mayo; Prateek Sharma
Journal:  Dig Dis Sci       Date:  2004-06       Impact factor: 3.199

3.  Clinically significant endoscopic findings in a multi-ethnic population with uninvestigated dyspepsia.

Authors:  Sanjiv Mahadeva; Khean-Lee Goh
Journal:  Dig Dis Sci       Date:  2012-06-12       Impact factor: 3.199

Review 4.  Adenocarcinoma of oesophagus: what exactly is the size of the problem and who is at risk?

Authors:  J Lagergren
Journal:  Gut       Date:  2005-03       Impact factor: 23.059

5.  Prognostic influence of Barrett's oesophagus and Helicobacter pylori infection on healing of erosive gastro-oesophageal reflux disease (GORD) and symptom resolution in non-erosive GORD: report from the ProGORD study.

Authors:  P Malfertheiner; T Lind; S Willich; M Vieth; D Jaspersen; J Labenz; W Meyer-Sabellek; O Junghard; M Stolte
Journal:  Gut       Date:  2005-06       Impact factor: 23.059

6.  Optimal treatment of laryngopharyngeal reflux disease.

Authors:  Irene Martinucci; Nicola de Bortoli; Edoardo Savarino; Andrea Nacci; Salvatore Osvaldo Romeo; Massimo Bellini; Vincenzo Savarino; Bruno Fattori; Santino Marchi
Journal:  Ther Adv Chronic Dis       Date:  2013-11       Impact factor: 5.091

Review 7.  The interplay between Helicobacter pylori, gastro-oesophageal reflux disease, and intestinal metaplasia.

Authors:  P Malfertheiner; U Peitz
Journal:  Gut       Date:  2005-03       Impact factor: 23.059

Review 8.  Barrett's oesophagus and oesophageal adenocarcinoma: how does acid interfere with cell proliferation and differentiation?

Authors:  R C Fitzgerald
Journal:  Gut       Date:  2005-03       Impact factor: 23.059

Review 9.  Single-isomer drugs: true therapeutic advances.

Authors:  Tommy Andersson
Journal:  Clin Pharmacokinet       Date:  2004       Impact factor: 6.447

10.  Influence of functional bowel disease on outcome of surgical antireflux procedures.

Authors:  David A Axelrod; Vasu Divi; Majet M Ajluni; Frederic E Eckhauser; Lisa M Colletti
Journal:  J Gastrointest Surg       Date:  2002 Jul-Aug       Impact factor: 3.452

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.